DURECT Corporation (DRRX)

Market Cap	76.18M
Revenue (ttm)	19.43M
Net Income (ttm)	-36.11M
Shares Out	27.60M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,121
Open	2.72
Previous Close	2.69
Day's Range	2.72 - 2.77
52-Week Range	2.64 - 9.50
Beta	1.49
Analysts	Strong Buy
Price Target	34.25 (+1,136.46%)
Earnings Date	Nov 1, 2023

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2000
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: DRRX

Financial Performance

In 2022, DURECT's revenue was $19.28 million, an increase of 37.96% compared to the previous year's $13.98 million. Losses were -$35.33 million, -2.57% less than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for DRRX stock is "Strong Buy." The 12-month stock price forecast is $34.25, which is an increase of 1,136.46% from the latest price.

Price Target

$34.25

(1,136.46% upside)

Analyst Consensus: Strong Buy